Nayeemuddin Mohammed, Daley Susan C, Ellsworth Pamela
AORN J. 2013 Oct;98(4):343-52. doi: 10.1016/j.aorn.2013.08.012.
In 2000, the US Food and Drug Administration approved the da Vinci Surgical System® for use in the United States. Since that time, the number of surgical robotic systems throughout the United States has continued to grow. The costs for using the system include the initial purchase ($1 million to $2.3 million) plus annual maintenance fees ($100,000 to $150,000) and the cost of limited-use or disposable instruments. Increasing the number of procedures that are performed using the robotic system can decrease the per-procedure costs. Two modifiable factors that contribute to increasing the annual caseload are increasing the number of surgeons capable of using the system and having a properly educated perioperative nursing team. An educated surgical team decreases turnover time, facilitates proper flow of each surgical procedure, and is able to actively and passively solve intraoperative problems.
2000年,美国食品药品监督管理局批准了达芬奇手术系统®在美国使用。自那时起,美国手术机器人系统的数量持续增长。使用该系统的成本包括初始购置费用(100万美元至230万美元)加上年度维护费用(10万美元至15万美元)以及一次性或有限使用器械的成本。增加使用机器人系统进行的手术数量可以降低每次手术的成本。有助于增加年度病例量的两个可改变因素是增加能够使用该系统的外科医生数量以及拥有受过良好教育的围手术期护理团队。受过良好教育的手术团队可减少周转时间,促进每个手术程序的顺利进行,并能够主动和被动地解决术中问题。